Bolt Biotherapeutics, Inc. Capital Expenditures Incurred but Not yet Paid
Bolt Biotherapeutics, Inc. (BOLT) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2025-08-14
- Bolt Biotherapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-06-30 was $0.00.
- Bolt Biotherapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-03-31 was $46.00K, a 80.09% decline year-over-year.
- Bolt Biotherapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-12-31 was -$174.00K, a 140.47% decline year-over-year.
- Bolt Biotherapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-09-30 was $84.00K, a 76.99% decline year-over-year.
- Bolt Biotherapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Bolt Biotherapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $152.00K, a 1800.00% increase from fiscal 2022.
- Bolt Biotherapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $8.00K, a 99.22% decline from fiscal 2021.
- Bolt Biotherapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $1.02M, a 3546.43% increase from fiscal 2020.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 | |||
| 2024-12-31 | $0.00 10-K · filed 2025-03-24 | |||
| 2024-06-30 | $37.00K 10-Q · filed 2025-08-14 | |||
| 2023-12-31 | $152.00K 10-K · filed 2025-03-24 | |||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $46.00K 10-Q · filed 2024-08-13 | -$128.00K derived: sum of 3 quarters · filed 2024-08-13 | -$44.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $46.00K 10-Q · filed 2024-05-14 | -$128.00K derived: sum of 2 quarters · filed 2024-05-14 | -$44.00K derived: sum of 3 quarters · filed 2024-05-14 | -$177.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$174.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$90.00K derived: sum of 2 quarters · filed 2024-03-21 | -$223.00K derived: sum of 3 quarters · filed 2024-03-21 | $8.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | $84.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$49.00K derived: sum of 2 quarters · filed 2023-11-09 | $182.00K 10-Q · filed 2023-11-09 | $612.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$133.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $98.00K 10-Q · filed 2023-08-07 | $528.00K derived: sum of 3 quarters · filed 2023-08-07 | $893.00K derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $231.00K 10-Q · filed 2023-05-11 | $661.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.03M derived: sum of 3 quarters · filed 2023-05-11 | $1.22M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $430.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $795.00K derived: sum of 2 quarters · filed 2023-03-29 | $984.00K derived: sum of 3 quarters · filed 2023-03-29 | $1.02M 10-K · filed 2023-03-29 |
| 2021-09-30 | $365.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $554.00K derived: sum of 2 quarters · filed 2022-11-10 | $591.00K 10-Q · filed 2022-11-10 | -$240.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $189.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $226.00K 10-Q · filed 2022-08-10 | -$605.00K derived: sum of 3 quarters · filed 2022-08-10 | -$26.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $37.00K 10-Q · filed 2022-05-12 | -$794.00K derived: sum of 2 quarters · filed 2022-05-12 | -$215.00K derived: sum of 3 quarters · filed 2022-05-12 | $48.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$831.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$252.00K derived: sum of 2 quarters · filed 2022-03-30 | $11.00K derived: sum of 3 quarters · filed 2022-03-30 | $28.00K 10-K · filed 2022-03-30 |
| 2020-09-30 | $579.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $842.00K derived: sum of 2 quarters · filed 2021-11-09 | $859.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $263.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $280.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $17.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |